Pre-Exposure Prophylaxis (PrEP)
Pre-exposure prophylaxis (or PrEP) is medicine taken to prevent getting HIV. PrEP is highly effective for preventing HIV when taken as prescribed.
- PrEP reduces the risk of getting HIV from sex by about 99%.
- PrEP reduces the risk of getting HIV from injection drug use by at least 74%.
PrEP is less effective when not taken as prescribed. Since PrEP only protects against HIV, condom use is still important for the protection against other STDs. Condom use is also important to help prevent HIV if PrEP is not taken as prescribed.
- PrEP Basics
- Let’s Stop HIV Together Campaign: Prevention Resources
- Pocket Guide: PrEP pdf icon[PDF – 479 KB] and Folding Instructions pdf icon[PDF – 1 MB]
- Info Sheet: PrEP 101pdf icon
- Video: PrEP
- Flyer: Paying for PrEPpdf icon
- Fact Sheet: Acute HIV Infection: Information about Acute HIV Infection and PrEP pdf icon[PDF – 221 KB]
- Fact Sheet: Truvada Medication Information Sheet for Patients pdf icon[PDF – 187 KB]
- Brochure: Now’s the Time to Find Out About PrEPpdf icon
- Brochure: PrEP Medication Guide – Reduce Your Risk of Getting HIVpdf icon
- Brochure: PrEP Is for Womenpdf icon
- Video: Are You Ready for PrEP?
- iPrEX: Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with menexternal icon. N Engl J Med 2010;363(27):2587-99.
- TDF2: Thigpen MC, Kebaabetswe PM, Paxton LA, et al; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswanaexternal icon. N Engl J Med 2012;367(5):423-34.
- Partners PrEP: Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and womenexternal icon. N Engl J Med 2012;367(5):399-410.
- Bangkok Tenofovir Study: Choopanya K, Martin M, Suntharasamai P, et al; Bangkok Tenofovir Study Groupexternal icon. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trialexternal icon. Lancet 2013;381(9883):2083-90.